Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research

Cancer. 2018 May 1;124(9):1859-1866. doi: 10.1002/cncr.31256. Epub 2018 Mar 2.

Authors

Aimée R Kreimer¹, Meredith S Shiels¹, Carole Fakhry², Mattias Johansson³, Michael Pawlita⁴, Paul Brennan³, Allan Hildesheim¹, Tim Waterboer⁵

Affiliations

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Head and Neck Surgery, Department of Otolaryngology, Johns Hopkins University, Baltimore, Maryland.
³ International Agency for Research on Cancer, Lyon, France.
⁴ Division of Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center, Heidelberg, Germany.
⁵ Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center, Heidelberg, Germany.

PMID: 29499070
DOI: 10.1002/cncr.31256

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aged
Aged, 80 and over
Biomarkers, Tumor / analysis
Early Detection of Cancer / methods*
Feasibility Studies
Female
Human papillomavirus 16 / isolation & purification*
Human papillomavirus 16 / pathogenicity
Humans
Incidence
Male
Mass Screening / methods*
Middle Aged
Oropharyngeal Neoplasms / diagnosis*
Oropharyngeal Neoplasms / epidemiology
Oropharyngeal Neoplasms / pathology
Oropharyngeal Neoplasms / virology
Papillomavirus Infections / diagnosis*
Papillomavirus Infections / epidemiology
Papillomavirus Infections / pathology
Papillomavirus Infections / virology
Research Design
SEER Program / statistics & numerical data
Serologic Tests / methods
Sex Factors
Survival Rate
United States / epidemiology

Substances

Biomarkers, Tumor

Grants and funding

001/WHO_/World Health Organization/International